手术在肺高级别神经内分泌肿瘤中的作用。

Role of surgery in high-grade neuroendocrine tumors of the lung.

作者信息

Bedirhan Mehmet Ali, Ürer Nur, Seyrek Yunus, Arda Naciye, Fener Neslihan, Cansever Levent, Kıyık Murat, Altın Sedat

机构信息

Department of Chest Disease, University of Health Sciences, Yedikule Training and Research Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Türkiye.

Department of Pathology, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Türkiye.

出版信息

Turk Gogus Kalp Damar Cerrahisi Derg. 2022 Jul 29;30(3):389-394. doi: 10.5606/tgkdc.dergisi.2022.19700. eCollection 2022 Jul.

DOI:10.5606/tgkdc.dergisi.2022.19700

PMID:36303705

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9580279/

Abstract

BACKGROUND

This study aims to evaluate the surgical results for high-grade neuroendocrine carcinomas and to identify factors that influence prognosis.

METHODS

Between January 2009 and December 2017, a total of 71 patients (58 males, 13 females; mean age: 62±9.6 years; range, 38 to 78 years) with a high-grade neuroendocrine carcinoma of the lung were retrospectively analyzed. Overall survival and five-year overall survival rates were evaluated.

RESULTS

The mean overall survival was 60.7±6.9 months with a five-year survival rate of 44.3%. The mean overall survival and five-year overall survival rates according to disease stage were as follows: Stage 1, 67±10.8 months (46%); Stage 2, 61.4±10.8 months (45%); and Stage 3, 33.2±8.6 months (32%) (p=0.02). The mean overall survival and five-year overall survival rate according to histological types were as follows: in large cell neuroendocrine carcinoma, 59.4±9.2 months (45%); in small cell neuroendocrine carcinoma, 68.6±12.2 months (43%); and in combined-type neuroendocrine carcinoma, 40.9±10.1 months (35%) (p=0.34).

CONCLUSION

Thoracic surgeons should be very selective in performing pulmonary resection in patients with Stage 3 high-grade neuroendocrine carcinomas and combined cell subtype tumors.

摘要

背景

本研究旨在评估高级别神经内分泌癌的手术结果，并确定影响预后的因素。

方法

回顾性分析2009年1月至2017年12月期间共71例（58例男性，13例女性；平均年龄：62±9.6岁；范围38至78岁）肺高级别神经内分泌癌患者。评估总生存期和五年总生存率。

结果

平均总生存期为60.7±6.9个月，五年生存率为44.3%。根据疾病分期的平均总生存期和五年总生存率如下：1期，67±10.8个月（46%）；2期，61.4±10.8个月（45%）；3期，33.2±8.6个月（32%）（p=0.02）。根据组织学类型的平均总生存期和五年总生存率如下：大细胞神经内分泌癌，59.4±9.2个月（45%）；小细胞神经内分泌癌，68.6±12.2个月（43%）；混合型神经内分泌癌，40.9±10.1个月（35%）（p=0.34）。